title: Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships.
abstract: A new model of 4-alkyl-1-arylpiperazines containing a terminal dihydronaphthalene fragment on the alkyl chain was synthesized in order to have mixed serotonergic and dopaminergic activity and to pursue the recent alternative approaches to the discovery of novel antipsychotic and anxiolytic agents. Title compounds were evaluated for in vitro activity on dopamine D-2 and serotonin 5-HT1A and 5-HT2 receptors by radioreceptor binding assays. They show high nanomolar affinity for 5-HT1A, moderate affinity for D-2, and low affinity for 5-HT2 receptors, and in particular, two compounds, 4-[3-(1,2-dihydro-6-methoxynaphthalen-4-yl)-n-propyl]-1-(2- methoxyphenyl)piperazine (8) and 4-[3-(1,2-dihydro-8-methoxynaphthalen-4-yl)-n-propyl]-1-(2- pyridyl)piperazine (15), show values (nM) of IC50 = 2.0 and 1.4 for 5-HT1A and IC50 = 90.6 and 119.3 for D-2, respectively. Some in vivo behavioral studies show compound 8 to be an antagonist on 5-HT1A receptors. These first findings place the new arylpiperazines on the same level as that of the azaspirone class, e.g., 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)-n-butyl]piperazine (NAN-190) and buspirone.
authors.affiliation: Dipartimento Farmaco-chimico, Università di Bari, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Perrone
authors.forename: F
authors.initials: F
authors.lastname: Berardi
authors.forename: N A
authors.initials: NA
authors.lastname: Colabufo
authors.forename: V
authors.initials: V
authors.lastname: Tortorella
authors.forename: F
authors.initials: F
authors.lastname: Fiorentini
authors.forename: V
authors.initials: V
authors.lastname: Olgiati
authors.forename: E
authors.initials: E
authors.lastname: Vanotti
authors.forename: S
authors.initials: S
authors.lastname: Govoni
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000378:metabolism; D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism; D007650:Ketanserin / Q000378:metabolism; D008297:Male; D015394:Molecular Structure; D009281:Naphthalenes / Q000138:chemical synthesis* / Q000494:pharmacology; D010879:Piperazines / Q000138:chemical synthesis* / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000187:drug effects* / Q000502:physiology; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000502:physiology; D013134:Spiperone / Q000378:metabolism; D013329:Structure-Activity Relationship; D014316:Tritium
chemical_list: D009281:Naphthalenes; D010879:Piperazines; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D014316:Tritium; C085372:4-(3-(1,2-dihydro-6-methoxynaphthalen-4-yl)-n-propyl)-1-(2-methoxyphenyl)piperazine; C085373:4-(3-(1,2-dihydro-8-methoxynaphthalen-4-yl)-n-propyl)-1-(2-pyridyl)piperazine; D013134:Spiperone; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D007650:Ketanserin